Drugs / SHR-3821
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06618651 | Nov 2024 → Jan 2026 overdue | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07515820 | Apr 2026 → Jul 2027 expected | colorectal cancer | Meng Qiu | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-3821 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06618651 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07515820 ↗ |